After a review of Portage Biotech Inc. (NasdaqCM:PRTG)'s funding requirements, the Board of Directors has made the decision to pause further drug development in the PORT-2 iNKT program. "This was a difficult decision considering the promising phase 1 safety and translational data from the non-small cell lung and melanoma trial," said Dr. Ian B. Walters, chairman and CEO, "As a result, the company will evaluate a range of potential strategic options which may include among other things, finding a partner for our iNKT program or other corporate transactions".
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.25 USD | -3.85% | +3.05% | -86.26% |
Apr. 15 | Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives | CI |
Apr. 12 | Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-86.26% | 5.14M | |
+0.67% | 42.86B | |
+12.51% | 42.74B | |
+44.30% | 41.36B | |
-6.20% | 27.68B | |
+6.41% | 25.15B | |
-23.60% | 18.63B | |
+27.61% | 12.37B | |
-3.32% | 11.92B | |
+7.05% | 11.21B |
- Stock Market
- Equities
- PRTG Stock
- News Portage Biotech Inc.
- Portage Biotech to Evaluate Range of Strategic Options